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Broadly neutralizing HIV antibodies (bNAbs) can recognize carbo-
hydrate-dependent epitopes on gp120. In contrast to previously
characterized glycan-dependent bNAbs that recognize high-mannose
N-glycans, PGT121 binds complex-type N-glycans in glycan microar-
rays. We isolated the B-cell clone encoding PGT121, which segregates
into PGT121-like and 10-1074–like groups distinguished by sequence,
binding afﬁnity, carbohydrate recognition, and neutralizing activity.
Group 10-1074 exhibits remarkable potency and breadth but no de-
tectable binding to protein-free glycans. Crystal structures of unli-
ganded PGT121, 10-1074, and their likely germ-line precursor reveal
that differential carbohydrate recognition maps to a cleft between
complementarity determining region (CDR)H2 and CDRH3. This cleft
wasoccupiedbyacomplex-typeN-glycan ina “liganded”PGT121struc-
ture. Swapping glycan contact residues between PGT121 and 10-1074
conﬁrmed their importance for neutralization. Although PGT121 binds
complex-type N-glycans, PGT121 recognized high-mannose-only HIV
envelopes in isolation andon virions. As HIV envelopes exhibit varying
proportions of high-mannose- and complex-type N-glycans, these re-
sults suggestpromiscuous carbohydrate interactions, anadvantageous
adaptation ensuring neutralization of all viruses within a given strain.
Antibodies are essential for the success of most vaccines (1),and antibodies against HIV appear to be the only correlate
of protection in the recent RV144 anti-HIV vaccine trial (2).
Some HIV-1–infected patients develop broadly neutralizing se-
rologic activity against the gp160 viral spike 2–4 y after infection
(3–10), but these antibodies do not generally protect infected
humans because autologous viruses escape through mutation
(11–13). Nevertheless, broadly neutralizing activity puts selective
pressure on the virus (13) and passive transfer of broadly neu-
tralizing antibodies (bNAbs) to macaques protects against simian/
human immunodeﬁciency virus (SHIV) infection (14–24). It has
therefore been proposed that vaccines that elicit such antibodies
may be protective against HIV infection in humans (10, 25–28).
The development of single-cell antibody cloning techniques
revealed that bNAbs target several different epitopes on theHIV-1
gp160 spike (29–35). The most potent HIV-1 bNAbs recognize
the CD4 binding site (CD4bs) (31, 34, 36) and carbohydrate-de-
pendent epitopes associated with the variable loops (32, 33, 37, 38),
including the V1/V2 (antibodies PG9/PG16) (33) and V3 loops
(PGTs) (32). Less is known about carbohydrate-dependent epit-
opes because the antibodies studied to date are either unique
examples or members of small clonal families.
To better understand the neutralizing antibody response toHIV-1
and the epitope targeted by PGT antibodies, we isolatedmembers of
a large clonal family dominating the gp160-speciﬁc IgG memory re-
sponse fromthe cladeA-infectedpatientwhoproducedPGT121.We
report that PGT121 antibodies segregate into two groups, a PGT121-
like anda10-1074–like group, according to sequence, bindingafﬁnity,
neutralizing activity, and recognition of carbohydrates and the V3
loop. The 10-1074 antibody and related family members exhibit
unusual potent neutralization, including broad reactivity against
newly transmitted viruses. Unlike previously characterized carbo-
hydrate-dependent bNAbs, PGT121 binds to complex-type, rather
than high-mannose, N-glycans in glycan microarray experiments.
Crystal structures of PGT121 and 10-1074 compared with struc-
tures of their germ-line precursor and a structure ofPGT121bound
to a complex-type N-glycan rationalize their distinct properties.
Results
Predominance and Diversity of PGT121 Clonotype. We recently iso-
lated gp140-speciﬁc IgG memory B cells from a clade A-infected
African donor [described as pt10 (39) or patient 17 (32)], usingYU-2
gp140 trimers as “bait.” Eighty-seven matching Ig heavy (IgH)- and
light (IgL)-chain genes corresponding to 23 unique clonal families
were identiﬁed.The IgHanti-gp140 repertoirewas dominated byone
clonal family representing ∼28% of all expanded B-cell clones (Fig.
1A). This B-cell family corresponds to the same clone as PGT121–
123 (32) and contained 38 members, 29 of which were unique var-
iants at the nucleotide level (Fig. 1A and SI Appendix, Table S1). On
the basis of their IgH nucleotide sequence, the PGT121 family
divides into two groups: a PGT121-like group containing PGT121–
123 and nine closely related variants and a second group, 10-1074–
like, containing 20 members (Fig. 1A). Although our traditional
primers (40, 41) did not amplify the IgL genes expressed by the
PGT121 B-cell clone due to the nucleotide deletions in the region
encoding framework region 1, 24 of 38 Igλ genes were obtained using
new Igλ-speciﬁc primers designed to amplify heavily somatically
mutated genes (SI Appendix, Table S1). Consistent with the high
levels of hypermutation in the IgH genes (18.2% of the VΗ gene on
average), the ampliﬁed Igλ genes were highly mutated (18.2% of the
Vλ gene on average) and carried nucleotide deletions in framework
region 1 (FWR1) (12–21 nt) and a 9-nt insertion in framework region
3 (FWR3) (SI Appendix, Fig. S1B and Table S1).
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We expressed 11 new unique variants (Fig. 1A and SI Ap-
pendix, Table S1) and demonstrated binding to YU-2 gp120 and
gp140 by ELISA and surface plasmon resonance (SPR) (Fig. 1
B–D). Unless otherwise noted, the gp120 and gp140 proteins
for these and other experiments were expressed in mammalian
cells that can attach either a complex-type or a high-mannose
N-glycan to a potential N-glycosylation site (PNGS). The level
of reactivity with gp120 differed between antibodies belonging
to the PGT121 and 10-1074 groups, the latter exhibiting higher
apparent afﬁnities (Fig. 1 C and D and SI Appendix, Fig. S2A)
mainly due to slower dissociation from gp120/gp140 for the
10-1074–related antibodies (SI Appendix, Fig. S2B).
PGT121 and 10-1074 Epitopes. Asn332gp120 in the vicinity of the V3
loop stem was reported as critical for binding and viral neutraliza-
tion by PGT121 (32); thus we examined the role of V3 in antigen
recognition by PGT121-like and 10-1074–like antibodies. ELISAs
were performed using HxBc2 gp120 “core” proteins that lack V1–
V3 loops (gp120core) or retain a portion ofV3 (2CC-core) and using
aYU-2 gp120mutant protein carrying a double-alanine substitution
in the V3 stem (gp120GD324-5AA). The tested antibodies showed
decreased reactivity against variants lacking the V3 loop and
gp120GD324-5AA compared with intact YU-2 gp120, with the binding
of 10-1074–group antibodies being themost affected (Fig. 1E and SI
Appendix, Fig. S3A andB). These results suggest that recognition by
both antibody groups involves protein determinants in the vicinity of
the V3 loop. None of the antibodies bound to overlapping peptides
spanning V3, suggesting the targeted epitopes are discontinuous
and/or require a particular conformation not achieved by isolated
peptides (Fig. 1E and SI Appendix, Fig. S3C).
Asn332gp120 [Asn337gp120 in earlier numbering (42)] is the N-
terminal residue of a PNGS deﬁned as the sequence Asn–X–Ser/
Thr. To determine whether Asn332gp120 and/or its N-linked glycan
are required for gp120 reactivity of the new PGT121-group and 10-
1074–group antibodies, we tested their binding to YU-2 gp120N332A
by ELISA. The N332A substitution diminished the binding of
PGT121 (32) and all of the new antibody variants, whereas their
reactivity against a mutant gp120 lacking a nearby glycosylation site
(gp120NNT301-3AAA mutant) was unchanged (Fig. 1E and SI Ap-
pendix, Fig. S4A). To determine whether a PNGS in addition to the
Asn332gp120 PNGS affects recognition by the new antibodies, we
constructed a series of 11 double-glycan mutants in which the
N332A mutation in YU-2 gp120 was combined with mutation of
PNGSs located betweenAsn262gp120 andAsn406gp120 (SI Appendix,
Fig. S5). All of the PGT121-like and 10-1074–like antibodies bound
to each of the double-glycan mutants with comparable afﬁnity to
that for gp120N332A (SI Appendix, Fig. S5), and thus we did not ﬁnd
another PNGS that further affected binding by PGT121-group or
10-1074–group antibodies.
To compare overall glycan recognition by the PGT121-like and
10-1074–like antibodies, we examined their binding to YU-2 gp120
treated with PNGase F, which cleaves both complex-type and high-
mannose N-glycans. Because gp120 cannot be fully deglycosylated
enzymatically unless it is denaturated, PNGase F treatment resulted
in partial deglycosylation of natively folded gp120 (SIAppendix, Fig.
S4B). Nevertheless, the reactivities of the two groups of antibodies
differed in that partial deglycosylation of gp120 by PNGase F de-
creased the binding activity of all PGT121-like antibodies but none
of the 10-1074–like antibodies (Fig. 1E and SI Appendix, Fig. S4C).
Similar experiments conducted with YU-2 gp120 treated with Endo
Fig. 1. PGT121 and 10-1074 clonal variants. (A) (Left)
Cytogram showing staining of pt10 PBMCs. (Center)
Pie chart showing the expansion of gp140-speciﬁc
IgG memory B cells. *, no matching IgL was initially
found. (Right) Dendrogram showing the relationship
between PGT121-like (blue) and 10-1074–like (green)
IgH protein sequences with PGT121, PGT122, PGT123,
and GL sequences (gray shading) included for com-
parison. Arrows indicate clones that were produced
as IgGs. Underlined clones were not identical at the
nucleotide level. *, no matching IgL could be am-
pliﬁed due to limited cDNA material. (B) ELISA
comparisons of binding. Curves show the binding of
10-1074–like (green) and PGT121-like (blue) anti-
bodies to YU-2 gp120. Black dashed and solid lines
show positive (10-188) and negative (mG053) con-
trols, respectively. (C) SPR sensorgrams showing the
binding of 10-1074 (green) and PGT121 (blue) to
YU-2 gp120 or gp140. Fits to a 1:1 binding model
are shown in black. RU, response units. (D) Appar-
ent KD values for the binding of 10-1074–like (green
dots) and PGT121-like (blue dots) antibodies to gp120
and gp140. **P < 0.005. (E) Heat map (expressed as
percentage of binding to unmodiﬁed gp120) sum-
marizing the binding of PGT121-like and 10-1074–
like antibodies [listed with a dendrogram showing
their relationships (A)] to diverse antigens (SI Ap-
pendix, Figs. S3–S8). Darker colors, stronger binding;
white, no observed binding. Anti-gp120V3 (10-188)
and anti-CD4bs (VRC01) antibodies are controls. For
V3 loop peptide-binding assays (V3 pept.) and gly-
can arrays, red indicates binding and white indicates
no binding. (F ) Competition ELISAs. Heat map
showing the relative binding to gp120 of selected
PGT121-like and 10-1074–like antibodies in the pres-
ence of potential competitor antibodies (SI Appendix,
Fig. S8). Results are expressed as percentage of bind-
ing in presence of 100 μg/mL of competitor compared
with binding in the absence of competitor. Darker
colors indicate stronger inhibition; white indicates
no competition.















H, which cleaves high-mannose, but not complex-type, N-glycans,
affected binding of 10-1074–like antibodies more than that of
PGT121-like antibodies (Fig. 1E and SI Appendix, Fig. S4D).
AnN-glycanmicroarray revealed that six of seven tested PGT121-
like antibodies showed detectable binding to complex-type mono- or
biantennary N-glycans terminating with galactose or α2–6-linked si-
alic acid but no detectable binding to high-mannose–type glycans,
corroborating and extending previous reports of no binding of
PGT121-123 to high-mannose N-glycans and no competition by
Man4 and Man9 dendrons for gp120 binding (32) (Fig. 1E and SI
Appendix, Fig. S6). In contrast, there was no detectable binding to
protein-free glycans by 10-1074–like antibodies (Fig. 1E and SI Ap-
pendix, Fig. S6). Although PGT121-like antibodies bound to protein-
free complex-type, but not high-mannose, N-glycans, PGT121-like
antibodies retained binding to YU-2 gp120 produced in cells treated
with kifunensine (gp120kif), a mannosidase inhibitor that results in
exclusive attachment of high-mannose glycans to PNGSs (43) (Fig.
1E and SI Appendix, Fig. S7B). Most of the PGT121-like antibodies
exhibited a small, but reproducible, decrease in binding to gp120kif.
By contrast, 10-1074–like antibodies retained full binding to gp120kif
(Fig. 1E and SI Appendix, Fig. S7B). These results are consistent with
the hypothesis that high-mannose, aswell as complex-type,N-glycans
can be involved in the epitope of PGT121-like antibodies.
Epitope-mapping experiments were performed with two repre-
sentative members of each group (PGT121 and 10-1369 for the
PGT121-like group and 10-1074 and 10-996 for the 10-1074–like
group) by competition ELISA. All four antibodies showed cross-
competition, but PGT121 more modestly inhibited the binding of
10-996 and 10-1074 to gp120 than vice versa (Fig. 1F and SI Ap-
pendix, Fig. S8). To further map the targeted epitopes, we used
anti-gp120 antibodies that recognize the crown of the V3 loop (SI
Appendix, Fig. S3C) (39, 44), the CD4bs (31, 44), the coreceptor
binding site [CD4-induced (CD4i)] (44), a constellation of high-
mannose N-glycans (2G12) (45–48), or the V3 loop and N-linked
glycans at positions 301 and 332 (PGT128) (32, 37). Anti-V3 crown
antibodies inhibited the binding of PGT121 and 10-1369 but did
not interferewith the binding of 10-996 and 10-1074 (Fig. 1F and SI
Appendix, Fig. S8). PGT128, and to a lesser extent 2G12, but not
the CD4bs and CD4i antibodies, diminished the binding of all four
antibodies to gp120 (Fig. 1F and SI Appendix, Fig. S8).
Taken together, these data suggest that PGT121 clonal mem-
bers recognize a site involving a protein determinant in the vicinity
of theV3 loop and theAsn332gp120-associated glycan (SIAppendix,
Discussion). However, the clone segregates into two families, the
PGT121-like and 10-1074–like groups, which differ in their afﬁn-
ities for gp120 and in the role of glycans in epitope formation.
Broad and Potent HIV Neutralization. To evaluate the neutralizing
activity of the new PGT121 variants, we measured their ability to
inhibit HIV infection of TZM-bl cells (49), using 10 viral strains
includingR1166.c1, which lacks the PNGSat gp120 position 332.All
PGT121 variants, including the 10-1074–like antibodies, neutralized
nine pseudoviruses and none neutralized the R1166.c1 control (Fig.
2A and SI Appendix, Table S2). Neutralizing activity correlated with
afﬁnity for the HIV spike, with the 10-1074 group showing slightly
greater potencies than the PGT121 group (Fig. 2B and SI Appendix,
Fig. S2C). A representative germ-line (GL) version of the PGT121/
10-1074 antibody clonotype (SI Appendix, Methods) failed to bind
gp120/gp140 or neutralize any viruses in the panel, implying that
somatic mutation is required for binding and neutralization (SI
Appendix, Fig. S9). PairingGL light chains withmutated 10-1074–or
10-996–group heavy chains failed to rescue binding or neutrali-
zation, suggesting that both mutated chains contribute to proper
assembly of the antibody paratope (SI Appendix, Fig. S9).
We next compared the neutralization activities of PGT121 and
two 10-1074–like antibodies (10-996 and 10-1074) against an ex-
tended panel of 119 difﬁcult-to-neutralize pseudoviruses (classiﬁed
as tier-2 and tier-3) (31) (SI Appendix, Tables S3 and S4). The 10-
996 and 10-1074 antibodies showed neutralization potencies and
breadth similar to those of PGT121 (Fig. 2C and SI Appendix, Fig.
S10 and Tables S3 and S4). As anticipated, most viruses bearing
amino acid changes at gp120 positions 332 and/or 334 (spanning the
Asn332–X–Ser334/Thr334 PNGS) were resistant to neutralization
(83.8% were resistant to PGT121, and 100% were resistant to
10-1074 and 10-996). Mutation at this PNGS accounted for the
majority of viruses resistant to neutralization (68.5% for 10-996,
72.5% for 10-1074, and 60.8% for PGT121) (SI Appendix, Table
S5). Comparable neutralization activities were observed for the IgG
and fragment antigen binding (Fab) forms of PGT121 and 10-1074,
suggesting that bivalency is not critical for their activity (Fig. 2D).
To evaluate the potential role of complex-type N-glycans on the
HIV envelope in neutralization by PGT121 and 10-1074, we pro-
duced high-mannose-only virions in two different ways: by assem-
bling pseudoviruses in cells treated with kifunensine, which results
in Man9GlcNAc2 N-linked glycans, or by assembly in HEK 293S
GnTI −/− cells, which results in Man5GlcNAc2 N-linked glycans
(50). We found that PGT121 neutralized two of three kifunensine-
derived PGT121-sensitive/10-1074–resistant strains equivalently to
their counterparts produced in wild-type cells (SI Appendix, Fig.
S7C). Two PGT121-sensitive/10-1074–sensitive viral strains pro-
duced in GnTI −/− cells were equally as sensitive to PGT121 and
Fig. 2. Neutralization activity of PGT121-like and 10-1074–like variants. (A) Heat
map comparing the neutralization potencies of PGT121-like and 10-1074–like
antibodies (listed at the topwith a dendrogram showing relationships; Fig. 1A) in
the TZM-bl assay. Darker colors, more potent neutralization; white, no neutral-
ization. (B) Correlation between the mean IC80 against nine viruses (y axis) and
apparent KD values for binding to gp120 and gp140 (x axis). (C) Graph com-
paring the neutralization breadth and potencies of PGT121, 10-996, and 10-1074
antibodies in the TZM-bl assay against an extended panel of 119 viruses. The y
axis shows the cumulative frequency of IC50 values up to the concentration
shown on the x axis. The spider graph (upper left) shows the frequency distri-
bution of neutralized viruses according to HIV-1 clades. (D) Dot plot showing
molar neutralization ratios (MNRs) (ratio of the Fab and IgG IC50 concentrations).
Horizontal bars represent the mean IC50s for all viruses. (E) Coverage graph (as
in C) comparing the neutralization breadth and potencies of selected bNAbs
against a panel of 95 clade B viruses as evaluated by the PBMC-based neutrali-
zation assay. (Right) Bar graph showing values for the normalized area under the
curve (NAUC) for the IgGs shown in the coverage graph. (F) Bar graph comparing
the neutralization potencies of PGT121 (blue) and 10-1074 (green) against
viruses isolated from historical (Hist.) and contemporary (Cont.) seroconverters.
ns, nonsigniﬁcant; **P < 0.005. Fold difference between median IC50s for the
neutralization of contemporary viruses by PGT121 and 10-1074 is indicated.
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10-1074 as their counterparts produced in wild-type cells. Consis-
tent with previous reports that complex-type N-glycans partially
protect theCD4binding site fromantibody binding (50), the viruses
produced inGnTI−/− cellsweremore sensitive toCD4-binding–site
antibodies (NIH45-46G54W and 3BNC60) (SI Appendix, Fig. S7D).
Newly Transmitted HIV-1.We next examined the activity of PGT121
and 10-1074 against transmitted founder viruses by evaluating
neutralization in a peripheral blood mononuclear cell (PBMC)-
based assay, using 95 clade B viruses isolated from a cohort of
individuals who seroconverted between 1985 and 1989 (historical
seroconverters, n= 14) or between 2003 and 2006 (contemporary
seroconverters, n = 25) (51, 52). We compared PGT121 and 10-
1074 with anti-CD4bs bNAbs (31) and other bNAbs including
VRC01, PG9/PG16, b12, 2G12, 4E10, and 2F5 (51, 52). Clus-
tering analyses of neutralization activity showed segregation into
two groups; the PGT121/10-1074 group contained the most active
HIV neutralizers including the anti-CD4bs and PG9 antibodies
(SI Appendix, Fig. S11A and Table S6). Remarkably, 10-1074
showed exceptional neutralization potency on this clade B virus
panel, exhibiting the greatest breadth at 0.1 μg/mL (67% of the 95
clade B viruses) of all bNAbs tested (Fig. 2E and SI Appendix, Fig.
S11B and Table S6). Although 10-1074 showed higher potency on
contemporary clade B viruses than PGT121 (∼20-fold differ-
ence), both antibodies were more effective against historical than
contemporary viruses (Fig. 2F and SI Appendix, Fig. S11C).
Crystal Structures of PGT121, 10-1074, and GL. To investigate the
structural determinants of the differences between PGT121-like
and 10-1074-like antibodies, we solved crystal structures of the Fab
fragments of PGT121, 10-1074, and a representativeGL precursor
at 3.0 Å, 1.9 Å, and 2.4 Å resolution, respectively (SI Appendix,
Table S7). Superimposition of the heavy- and light-chain variable
domains (VH and VL) among the three Fabs showed conservation
of the backbone structure, with differences limited to small dis-
placements of the complementarity determining region (CDR)
H3 and CDRL3 loops of the afﬁnity-matured Fabs relative to GL
(Fig. 3A and SI Appendix, Fig. S12 and Table S8).
An unusual feature shared by the antibodies is their long (25
residues) CDRH3 loop, which forms a two-stranded antiparallel
β-sheet extending theVH domain F andG strands (Fig. 3B). In each
Fab, the tip of the extended CDRH3 loop primarily contains non-
polar residues (Fig. 3B). A similar structural feature was observed
for theCDRH3ofPGT145, a carbohydrate-sensitive antibodywhose
epitope involves the gp120V1V2 loop (38). However, the extended
two-stranded β-sheet of PGT145’s CDRH3 contains mostly nega-
tively charged residues, including two sulfated tyrosines at the tip.
Aligning VH-VL of PGT121 and PGT145 (SI Appendix, Table S8)
shows that CDRH3PGT145 extends past CDRH3PGT121 and that its
tip and VH domain are aligned, whereas the CDRH3s of PGT121,
10-1074, andGL tilt towardVL (SIAppendix, Fig. S13A). The tilting
of CDRH3PGT121/CDRH310-1074/CDRH3GL toward VL opens a
cleft between CDRH2 and CDRH3 (Fig. 3 C andD), a feature not
shared by related antibodies (SI Appendix, Fig. S13).
PGT121 and 10-1074 are highly divergent with respect toGL and
each other (of 132 residues, PGT121VH differs from 10-1074VH and
GLVHby 36 and45 residues, respectively, and10-1074VH andGLVH
differ by 29) (Fig. 3 and SI Appendix, Fig. S14). The majority of the
PGT121/10-1074 differences are located in the CDRVH loops and
CDRL3. Interestingly, six substitutions in CDRH3 (residues 100d,
100f, 100h, 100j, 100l, and 100n) alternate such that every second
residue is substituted, causing resurfacing of the cleft between
CDRH2 and CDRH3 that results from CDRH3 tilting toward VL
(Fig. 3 C andD). This region likely contributes to the different ﬁne
speciﬁcities of PGT121 and 10-1074. Five other solvent-exposed
substitutions in heavy-chain framework region 3 (FWR3HC) (resi-
dues 64, 78, and 80–82; strands D and E) are potential antigen
contact sites (Fig. 3 C and D and SI Appendix, Fig. S14) given that
framework regions inHIVantibodies can contact gp120 (31, 36, 53).
Other differences that may contribute to ﬁne speciﬁcity differences
include a negative patch on PGT121 in the vicinity of Asp56HC not
present in 10-1074 orGL (Ser56HC in 10-1074 andGL) and positive
patches on the CDRL1 and CDRL3 surface not found on the
analogous surface of GL (SI Appendix, Fig. S15).
Somatic mutations common to PGT121 and 10-1074 may be
involved in shared features of their epitopes. The heavy chains of
PGT121 and 10-1074 share only three common mutations (of 36
PGT121–GL and 29 10-1074–GL differences) (Fig. 3 C and D).
In contrast, PGT121 and 10-1074 share 18 common light-chain
mutations (of 37 PGT121–GL and 36 10-1074–GL differences),
including an insertion in light-chain FWR3 that causes bulging of
the loop connecting strands D and E (Fig. 3 C and D and SI
Appendix, Fig. S12), and the substitution of Asp50LC-Asp51LC in
CDRL2GL to Asn50LC-Asn51LC in both PGT121 and 10-1074,
resulting in a less negatively charged surface (SI Appendix, Fig.
S15). The large number of common substitutions introduced into
light chain (LC)PGT121 and LC10-1074 (∼50% of LC substitutions)
points to CDRL1, CDRL2, and FWR2LC as potential contact
regions for epitopes shared by PGT121 and 10-1074.
We next made comparisons with the structure of PGT128, which
recognizes Asn332gp120- and Asn301gp120-linked glycans and V3 and
was solved as a complex with an outer-domain/mini-V3 loop gp120
expressed in cells that cannot produce complex-type N-glycan–mod-
iﬁedproteins (37).Unlike theCDRH3loopsofPGT121and10-1074,
PGT128CDRH3 is not tilted toward PGT128VL, and CDRH3PGT128
does not include a two-stranded β-sheet (SI Appendix, Fig. S13). In
addition, CDRH3PGT128 (18 residues) is shorter than theCDRH3s of
PGT121 and 10-1074 (24 residues), whereas CDRH2PGT128 contains
a 6-residue insertion not found in PGT121 or 10-1074. Due to these
differences, CDRH2 is the most prominent feature in PGT128,
whereas CDRH3 is most prominent in PGT121 and 10-1074 (SI
Appendix, Fig. S13). CDRH2PGT128 and CDRL3PGT128 together
recognize Man8/9 attached to Asn332gp120, and CDRH3PGT128 con-
tacts theV3 loop base. Thismodeof gp120 recognition is not possible
for PGT121 and 10-1074 because the structural characteristics of
their CDRH2 and CDRH3 loops differ signiﬁcantly from those
of PGT128 (SI Appendix, Fig. S13), consistent with the ability of
PGT128 (37), but not PGT121 and 10-1074 (SI Appendix, Fig. S6),
to recognize protein-free high-mannose glycans.
Crystal Structure of PGT121–Glycan Complex. A 2.4-Å resolution
structure of PGT121 associated with a complex-type sialylated
Fig. 3. Comparison of PGT121, 10-1074, and GL Fab structures. (A) Cα
alignment of variable domains of PGT121 (VHPGT121, blue; VLPGT121, light blue),
10-1074 (VH10-1074, green; VL10-1074, light green) and GL (VHGL, dark gray;
VLGL, light gray) (CDRs for 10-1074 are magenta). An N-acetylglucosamine
attached to PGT121 Asn105HC is depicted as sticks. (B) CDRH3 loops of PGT121
and 10-1074. Extensions of the VH domain F (white) and G (grey) strands (only
main chain atoms shown) form CDRH3, a two-stranded β-sheet in PGT121
(blue), 10-1074 (green), and GL (main and side chain atoms shown; main
chain hydrogen bonds are yellow dashes). (C and D) Surface representation
of PGT121 (C) and 10-1074 (D) variable domains showing differences (yellow)
and somatic mutations in common (purple). PGT121 HC, blue; PGT121 LC,
light blue; 10-1074 HC, green; 10-1074 LC, light green.















biantennary glycan was solved (Fig. 4 and SI Appendix, Table S7)
using crystals obtained under conditions including NA2, a com-
plex-type asialyl biantennary glycan (SI Appendix, Fig. S6). Sur-
prisingly, the glycan bound to PGT121 in our crystal structure was
not NA2, but rather a complex-type N-glycan from a neighboring
PGT121 Fab in the crystal lattice: speciﬁcally the N-glycan at-
tached to Asn105HC (SI Appendix, Fig. S16A). The glycan identity
is evident because there was electron density for the glycosidic
linkage to Asn105HC and for a terminal sialic acid on the Manα1–
3Man antenna (the galactose and sialic acid moieties of the
Manα1–6Man antenna were unresolved) (SI Appendix, Fig. S17A).
The composition of the bound glycan corresponds to a portion of
the α2–6-sialylated A2(2–6) glycan that was bound by PGT121 in
microarray experiments (SI Appendix, Fig. S6) and to the expected
sialyl linkage on complex-type N-glycans attached to PNGS on
proteins expressed in HEK293T cells (54). Although the VH-VL
domains of this structure (“liganded” PGT121) superimpose with
no signiﬁcant differences onto the VH-VL domains of the PGT121
structure with no bound N-glycan (“unliganded” PGT121) (SI
Appendix, Fig. S16B and Table S8), the elbow bend angle (angle
between the VH–VL and CH1–CL pseudodyads) differs between
the structures (SIAppendix, Fig. S16). This difference likely reﬂects
ﬂexibility that allows the Fab to adopt variable elbow bend angles
depending upon crystal lattice forces.
Given that we observed binding of complex-type N-glycan in
one crystal structure (the liganded PGT121 structure) but not in
another structure (the unliganded PGT121 structure), we esti-
mate that the afﬁnity of PGT121 for complex-type N-glycan not
attached to gp120 is in the range of the concentration of PGT121
in crystals (∼10 mM). If we assume that the KD for binding
isolated glycan is in the range of 1–10 mM, comparable to the
1.6-mM KD derived for PG9 binding to Man5GlcNAc2-Asn (38),
then the KD for PGT121 binding of isolated glycan represents
only a minor contribution to the afﬁnity of PGT121 for gp120,
which is in the nanomolar range (SI Appendix, Fig. S2A).
The glycan in the liganded PGT121 structure interacts exclu-
sively with the VH domain and makes extensive contacts with res-
idues in all three CDRs (buried surface area on PGT121HC = 600
Å2). Contacts include 10 direct and 18 water-mediated hydrogen
bonds (SI Appendix, Table S9) with 9 aa anchoring the glycan be-
tween the N-acetylglucosamine moiety linked to the branch-point
mannose and the terminal sialic acid on the 1–3 antenna (Fig. 4
and SI Appendix, Fig. S17B). Several contacts with PGT121 are
made by this sialic acid, including three direct hydrogen bonds
with PGT121 residues Asp31HC and His97HC in addition to water-
mediated hydrogen bonds with Asp31HC. The sialic acid also con-
tributes to a water-mediated intraglycan hydrogen bond network
(Fig. 4). The direct contacts with sialic acid may explain the
stronger binding of PGT121 to the sialylated A2(2–6) glycan than
to the asialylated NA2 glycan in our glycan microarray analysis
(SI Appendix, Fig. S6). Extensive water-mediated protein contacts
established by the N-acetylglucosamine and galactose moieties of
the 1–3 antenna could explain the binding observed for asialylated
mono- and biantennary glycans to PGT121 (SI Appendix, Fig. S6).
Six of the residues contributing direct or likely amino acid side-
chain contacts to the glycan (Ser32HC-CDRH1, Lys53HC-CDRH2,
Ser54HC-CDRH2, Asn58HC-CDRH2, His97HC-CDRH3, and
Thr100lHC-CDRH3) differ from those on 10-1074 (Tyr32HC-CDRH1,
Asp53HC-CDRH2, Arg54HC-CDRH2, Thr58HC-CDRH2, Arg97HC-CDRH3,
and Tyr100lHC-CDRH3) and are highly conserved among PGT121-
like, but not 10-1074–like, antibodies (Fig. 4D). The 10-1074 resi-
dues lack the corresponding functional groups to make the ob-
served glycan contacts or have bulky side chains that would cause
steric clashes (SI Appendix, Fig. S14). Four of these residues also
differ from those on the GL (Tyr32HC-CDRH1, Tyr53HC-CDRH2,
Gln97HC-CDRH3, and Tyr100lHC-CDRH3), suggesting that the lack of
binding of 10-1074–like antibodies andGL to protein-free complex-
type glycans in our glycan microarrays results from missing hydro-
gen bonds and/or steric clashes (e.g., His97PGT121 vs. Arg9710-1074
and/or Thr100lPGT121 vs. Tyr100l10-1074). As the majority of se-
quence differences between PGT121 and 10-1074 cluster in the
CDRH loops (Fig. 3C andD), speciﬁcally to the surface of the cleft
between CDRH2 and CDRH3 where we observe the bound com-
plex-typeN-glycan (Fig. 4), differential recognition of complex-type
glycans on gp120 may account for some or all of the differences in
their ﬁne speciﬁcity observed in our functional experiments (Figs.
1, 2, and 4 and SI Appendix, Figs. S1–S8).
Substitution of Glycan-Contacting Antibody Residues Affects Neutrali-
zation. To evaluate the contributions of complex-type N-glycan
contacting residues identiﬁed from the liganded PGT121 structure,
we generated two mutant antibodies designed to exchange the
complex-type glycan-contacting residues between PGT121 and 10-
1074: a 10-1074 IgG with PGT121 residues (six substitutions in IgH:
Y32S, D53K, R54S, T58N, R97H, and Y100lT) and a PGT121 IgG
with reciprocal substitutions. The “glycomutant” antibodies (10-
1074GM and PGT121GM) exhibited near–wild-type apparent afﬁnity
for YU-2 gp120/gp140 as measured by SPR (Fig. 5 A and B),
demonstrating that the substitutions did not destroy binding to an
envelope spike derived from a viral strain neutralized by both
PGT121 and 10-1074 (Fig. 2A). The fact that PGT121 complex-type
N-glycan contacting residues can be accommodated within the 10-
Fig. 4. Crystal structureof a ligandedPGT121. (A) Ribbondiagramof thePGT121
variable domains bound to a complex-type N-glycan (yellow sticks) attached
to Asn105HC of a neighboring Fab in the crystal. VH is blue with CDRs highlighted
in teal, VL is light blue, side-chain and backbone atoms of contact residues are
depicted as sticks, hydrogen bonds are magenta dashed lines, and water mole-
cules are red spheres. (B) Schematic of the bound complex-type glycan. Glycan
residues in the dashed boxwere disordered. Fucose (FUC), red triangles; galactose
(GAL), yellow circles; mannose (MAN), green circles; N-acetyl glucosamine (NAG),
blue squares; sialic acid (SIA), magenta diamonds. (C) Surface representation of
PGT121 variable domainswith bound glycan (sticks). Coloring is as inA. (D) Amino
acid alignment comparing residues at positions 32, 53, 54, 58, 97, and 100l (resi-
dues of PGT121 making direct or likely contacts with N-glycan; amino acid num-
bering based on crystal structures) between PGT121-like (blue) and 10-1074–like
(green) antibodies. Framework (FWR) and complementarity determining regions
(CDR) (Upper), dendrogram showing relationships (Left), and binding to protein-
free glycans as detected in glycan arrays (Right; red indicates binding, white
indicates no binding) are indicated. Gray shading indicates amino acid identity.
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1074 background without destroying binding to a gp120/gp140
bound by both wild-type antibodies implies overall similarity in an-
tigen binding despite ﬁne speciﬁcity differences.
Unlike wild-type PGT121, PGT121GM showed no glycan bind-
ing in microarray experiments, conﬁrming that 10-1074 residues at
the substituted positions are not compatible with protein-free
glycan binding (Fig. 5C) and supporting the suggestion that resi-
dues contacting the glycan in the liganded PGT121 structure are
involved in recognition of complex-type glycans in themicroarrays.
The 10-1074GM protein also showed no binding to protein-free
glycans (Fig. 5C), indicating the involvement of residues in addi-
tion to those substituted in creating the binding site for a protein-
free complex-type N-glycan.
We next used a TZM-bl–based assay to compare neutralization of
the wild-type and glycomutant antibodies. We tested 40 viral strains
including strains differentially resistant to PGT121 or 10-1074 and
strains sensitive to both wild-type antibodies (Fig. 5 D and E and SI
Appendix, Table S10). Consistent with the binding of PGT121GM
and 10-1074GM to puriﬁed YU-2 envelope proteins (Fig. 5A), both
mutants neutralized the YU-2 virus (Fig. 5D); however, 64% of the
PGT121-sensitive strains were resistant to PGT121GM (Fig. 5 D and
E and SI Appendix, Table S10), suggesting that the glycan-contacting
residues identiﬁed in the liganded PGT121 structure are relevant to
the neutralization activity of PGT121. Conversely, 10-1074GM ex-
hibited a higher average potency than wild-type 10-1074 against the
10-1074–sensitive strains (Fig. 5E and SI Appendix, Table S10), in-
cluding potency increases of more than threefold against four 10-
1074–sensitive strains (WITO4160.33, ZM214M.PL15, Ce1172_H1,
and 3817.v2.c59). In general, the PGT121 substitutions into 10-1074
did not confer sensitivity to 10-1074GM upon PGT121-sensitive/
10-1074–resistant strains; however, two of these strains (CNE19
and 62357_14_D3_4589) became sensitive to 10-1074GM (IC50s =
0.19 μg/mL and 40.8 μg/mL, respectively) (Fig. 5D). Interestingly,
these are the only PGT121-sensitive/10-1074–resistant strains that
include an intact Asn332gp120-linked PNGS (Fig. 5D). The other
PGT121-sensitive/10-1074–resistant strains lack the Asn332gp120-
linked glycan and are resistant to PGT121GM and 10-1074GM, im-
plying that their sensitivity to wild-type PGT121 involves a nearby
N-glycan and/or compensation by protein portions of the epitope (SI
Appendix, Discussion). Although a dramatic gain of function was
observed only for 10-1074GM against one strain (CNE19), this result,
together with the general improvement observed for 10-1074GM
against 10-1074–sensitive strains (Fig. 5E), is consistent with the
interpretation that the crystallographically identiﬁed glycan-
contacting residues can transfer PGT121-like recognition proper-
ties to 10-1074 in some contexts and/or affect its potency in others.
In addition, the loss of neutralization activity for PGT121GMagainst
PGT121-sensitive strains demonstrates that neutralization activity
of PGT121 involves residues identiﬁed as contacting complex-type
N-glycan in the liganded PGT121 structure.
Discussion
TheHIV spike is covered by carbohydrates that can act as a shield to
protect the virus against antibodies (13, 50). This strategy appears to
be largely successful in most infected individuals, although a small
number of patients develop bNAbs that bind in part to glycans
(32, 33, 47). The involvement of glycan recognition in the activities of
bNAbs against HIV-1 ranges from that of 2G12, which binds a con-
stellation of high-mannose glycans with little input from speciﬁc
protein binding (47), toPG9,which recognizes high-mannose glycans
and protein (38). Complex-type glycan recognition by HIV-1 bNAbs
has not been previously documented. Here we describe the prop-
erties of bNAbs related to PGT121, some of which, like PGT121,
recognize complex-type N-glycans in protein-free microarrays.
PGT121 is a glycan-dependent bNAb that was originally identi-
ﬁed in the serum of a clade A-infected donor in a functional screen
Fig. 5. Binding and neutralization activities of PGT121GM and 10-1074GM mutant antibodies. (A) SPR sensorgrams showing the binding of PGT121GM (light
green) and 10-1074GM (light blue) to YU-2 gp120 or gp140. (B) Bar graphs comparing apparent KD values for the binding of 10-1074, PGT121, PGT121GM, and
10-1074GM antibodies to gp120 and gp140. Error bars indicate the SEM of KD values obtained from three independent experiments. Fold differences between
KD values of wild-type vs. glycomutant antibodies are indicated. (C) Bar graphs comparing binding of glycans (SI Appendix, Fig. S6A) by PGT121 and 10-1074
with mutant antibodies (PGT121GM and 10-1074GM). Numerical scores of binding are measured as ﬂuorescence intensity (means at duplicate spots) for probes
arrayed at 5 fmol/spot. (D) Graphs comparing IC50 values for neutralization of selected viruses by PGT121, 10-1074, PGT121GM, and 10-1074GM in the TZM-bl
assay. Viral strains are listed with PNGSs at the indicated gp120 positions (those near Asn332gp120) color coded: dark gray, a PNGS; white, not a PNGS. From the
2012 Los Alamos ﬁltered web alignment of ∼2,865 gp120 sequences, the frequencies of PNGSs at these positions are 295 (58.3%), 301 (91.7%), 332 (73.0%),
334 (20.4%), 386 (86.7%), 392 (79.4%), 396 (25.7%), 406 (5.5%), 446 (7.6%), and 448 (85.6%). Gray shading indicates PGT121-sensitive viruses that were not
neutralized by PGT121GM and a 10-1074–resistant strain that was neutralized by 10-1074GM. (E) Coverage graph comparing the neutralization breadth and
potencies of PGT121, PGT121GM, 10-1074, and 10–1074GM antibodies in the TZM-bl assay against a panel of 40 viruses.















yielding only two clonally related members (32). We used gp140
trimers as bait for single-cell sorting (44) to isolate 29 new clonal
variants of PGT121 (39). The PGT121 clonal family includes dis-
tinct groups of closely related antibodies: the PGT121 and 10-1074
groups. Our results suggest that the epitopes of both groups involve
the PNGS at Asn332gp120 and the base of the V3 loop (SI Appendix,
Discussion). Serological studies of broad and potent anti–HIV-1
antibodies in humans and SHIV-infected macaques demonstrate
that theAsn332gp120 PNGS is a frequent target on theHIV spike (6,
55–58). The PGT121-like and 10-1074–like antibody groups differ
in amino acid sequences, gp120/gp140 binding afﬁnities, and neu-
tralizing activities, with the 10-1074–like antibodies being com-
pletely dependent for neutralization upon an intact PNGS at
Asn332gp120, whereas PGT121-like antibodies were able to neu-
tralize some viral strains lacking the Asn332gp120 PNGS (SI Ap-
pendix, Discussion). Thus, the immune response in the PGT121
donor developed a mechanism to overcome variations in the HIV
glycan shield in part by producing clonal antibody variants with
different ﬁne speciﬁcities for recognizing an epitope at or near the
Asn332gp120 PNGS.
A notable difference between the two antibody groups is that the
PGT121-like antibodies bound complex-type N-glycans in carbo-
hydrate arrays, whereas the 10-1074–like antibodies showed no
detectable binding to any of the protein-free N-glycans tested (SI
Appendix, Fig. S6). Protein-free glycan binding by anti-HIV anti-
bodies is not always detectable; e.g., although PG9 recognizes
a gp120-associated high-mannose glycan (38), no binding to pro-
tein-free glycans was detected in microarrays. Thus, although
a positive result in a glycan microarray implies involvement of
a particular glycan in an antibody epitope, a negative result does
not rule out glycan recognition. For example, although not de-
tectable in the glycan microarray experiments, high-mannose gly-
cans may be involved in the PGT121 epitope, consistent with
binding and neutralization of high-mannose-only forms of gp120
protein and virions (SI Appendix, Fig. S7).
The molecular basis for the differences between PGT121, 10-
1074, and their GL progenitor was revealed in part by their crystal
structures. The ﬁnding that the majority of light-chain somatic
mutations are shared between PGT121 and 10-1074, whereas
mutations in the heavy chains differ, suggests that the light-chain
contacts shared portions of the gp120 epitope and the heavy chain
recognizes distinct features. All three antibodies exhibit an ex-
tended CDRH3 with a nonpolar tip that may allow accessing of
cryptic epitopes. Differences in the antigen-binding site of the two
mature Fabs were mainly localized to a cleft between CDRH2 and
the extended CDRH3 (Fig. 3 C and D and SI Appendix, Fig. S14).
Interestingly, the putative antigen-binding cleft between CDRH2
and CDRH3 was also found in a representative germ-line pro-
genitor of PGT121 and 10-1074.
We obtained structural information concerning glycan recogni-
tion by PGT121-like antibodies from a crystal structure in which
a complex-type sialylated N-glycan attached to a VH domain resi-
due interacted with the combining site of a neighboring PGT121
Fab (SI Appendix, Fig. S16A). Several features of the liganded
PGT121 structure suggest it is relevant for understanding the rec-
ognition of complex-type N-glycans on gp120 by PGT121-like
antibodies. First, the glycan in the structure corresponds to the α2–
6 sialylated glycan A2(2–6) that PGT121 binds in microarrays (SI
Appendix, Fig. S6). Second, the glycan interacts with PGT121 using
the cleft between CDRH3 and CDRH2 that was suggested by
structural analyses to be involved in epitope recognition, potentially
explaining the unusual tilting of CDRH3 toward VL in the PGT121
and 10-1074 structures (Fig. 3 and SI Appendix, Fig. S13). Third,
most of the VH residues identiﬁed as interacting with the glycan
differ between PGT121 and 10-1074 (Fig. 3C andD), rationalizing
different binding proﬁles in glycan microarrays and potentially
explaining the different ﬁne speciﬁcities revealed in protein-bind-
ing experiments (Fig. 1). Fourth, swapping crystallographically
identiﬁed glycan contact residues between PGT121 and 10-1074 in
part transferred their properties: PGT121GM, like 10-1074, did not
bind to protein-free glycans, but both PGT121GM and 10-1074GM
preserved near–wild-type binding to puriﬁed YU-2 gp120/gp140.
Although PGT121GM retained the ability to neutralize some viral
strains that were neutralized by wild-type PGT121 and 10-1074, it
failed to neutralize strains that are PGT121 sensitive/10-1074 re-
sistant (Fig. 5D), demonstrating that the glycan-binding motif is
essential for the neutralizing activity of PGT121 against 10-1074–
resistant strains. For the reciprocal swap, the neutralization po-
tency of 10-1074GMwas increased or unaffected relative to 10-1074,
and, in one case, 10-1074GM potently neutralized a PGT121-sen-
sitive/10-1074–resistant strain, consistent with transfer of the crys-
tallographically identiﬁed glycan motif and the hypothesis that the
epitopes of PGT121-like and 10-1074–like antibodies are related.
Taken together, these observations argue that at least part of the
glycan epitope recognized by PGT121-like antibodies is revealed by
the liganded PGT121 structure.
In the absence of a cocrystal structure of an antibody–gp120
complex, it is difﬁcult to determine the molecular details of the
involvement of N-glycan in recognition by PGT121-related anti-
bodies. The ﬁndings to be reconciled include (i) protein-free
complex-type N-glycan binding by PGT121-like, but not 10-1074–
like, antibodies; (ii) recognition by both antibody families of high-
mannose-only forms of HIV envelopes in solution and on virions;
(iii) epitope mapping studies reported here and previously for
PGT121 (32), implicating the Asn332gp120 PNGS; and (iv) muta-
genesis studies reported here and previously for PGT121 (32) that
failed to ﬁnd a second PNGS affecting binding or neutralization.
One interpretation of these ﬁndings is that PGT121-like
antibodies exhibit promiscuous carbohydrate recognition prop-
erties such that they could accommodate either a complex-type
or a high-mannose N-glycan attached to Asn332gp120. However,
this PNGS is generally assumed to carry high-mannose N-glycans
on the basis of mass spectrometry data (50, 59–67) and the fact
that it forms a critical part of the epitope recognized by the high-
mannose–speciﬁc antibody 2G12 (46, 47). Nonetheless, the
possibility of complex-type glycan at this position under some
circumstances remains open given that the Asn332gp120-linked N-
glycan has been reported to be a mixture of high mannose and
complex type in gp140s from some viral strains (42). In general,
deﬁnitive assignment of glycan composition on HIV-1 envelope
spikes is complicated by studies showing that the composition of
N-linked glycans is heterogeneous within a single viral strain or
puriﬁed envelope construct and can differ at individual PNGSs
on the basis of the viral strain and whether the glycans were
analyzed on virions or puriﬁed proteins. In the case of virions,
glycan composition can depend on whether virions were pro-
duced as pseudoviruses or from a single-plasmid production
system, and, in the case of puriﬁed proteins, glycan composition
can differ depending on the oligomeric state of the puriﬁed
envelope being examined (monomeric gp120 vs. trimeric gp140)
and the cell type used for expression (42, 50, 59–63, 65). Indeed,
marked cell-to-cell differences are known to occur in carbohy-
drate sequences within established cell lines (68).
A second interpretation of the available data is that PGT121-
like antibodies have binding sites that can accommodate a high-
mannose glycan attached to Asn332gp120 and either a complex-
type or a high-mannose N-glycan attached to a second, as yet
unidentiﬁed, PNGS that was not detected in our mutagenesis
experiments (SI Appendix, Fig. S5) or those previously conducted
for PGT121 (32). Unfortunately, there is no direct way to assess
the nature of the glycan(s) recognized at the Asn332gp120 PNGS
and/or a putative second PNGS because it is not possible to
selectively convert one or all PNGSs to exclusively complex-type
glycans on virions or recombinant proteins. Thus, although we
were able to demonstrate binding to and neutralization of high-
mannose-only proteins and virions by PGT121-like and 10-1074–
like antibodies, we cannot perform the reciprocal experiment to
assess binding and neutralization of complex-type-only proteins
and virions. Nonetheless, adding the discovery that PGT121 can
bind complex-type N-glycans to the literature describing high-
mannose N-glycan recognition by HIV antibodies (32, 33, 37, 38,
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46, 47) suggests that the host immune system can respond to
both high-mannose and complex-type glycans on gp120.
Given that any changes in the Asn332gp120 PNGS (substitutions
at either position 332 or 334) affect neutralization by 10-1074–like
antibodies (SI Appendix, Table S5), their epitopes likely also in-
clude Asn332gp120-attached glycan or, alternatively, a glycan-
modulated conformational protein epitope. As 10-1074–like anti-
bodies showed no detectable binding to any protein-free glycans
(SI Appendix, Fig. S6), we have no information about the nature of
their putatively recognized glycan(s). However, our data suggest
the possibility that 10-1074–like and PGT121-like antibodies have
different glycan preferences, with 10-1074–like antibodies pre-
ferring high-mannoseN-glycans to complex type, and PGT121-like
antibodies exhibiting the opposite preference. This speculation is
consistent with Endo H treatment of gp120 that contained both
complex-type and high-mannose N-glycans, resulting in a greater
decrease in binding of 10-1074–like than PGT121-like antibodies
(Fig. 1E) and gp120kif showing decreased binding to PGT121-like
antibodies, but equivalent binding to 10-1074–like antibodies. In
addition, the concentration of sequence differences between
PGT121 and 10-1074 in the glycan-binding site of PGT121 (Figs. 3
and 4) suggests structurally distinct features of their related epit-
opes, which could be accessed by slightly different angles of ap-
proach to binding of gp120 within an envelope spike.
Although further studies will be required to deﬁne the details,
our results raise the possibility that recognition of gp120 glycans
by HIV antibodies such as PGT121 can involve both high-man-
nose and complex-type N-glycans in a carbohydrate-dependent
epitope. Other carbohydrate-dependent HIV antibodies, such as
PGT128, may share this property. This would be an advanta-
geous adaptation of the host immune system to deal with het-
erogeneous N-glycan compositions on HIV-1 envelope spikes.
The PGT128/gp120 outer domain–V3 crystal structure reveals
a mechanism by which promiscuous recognition of either com-
plex-type or high-mannose N-glycan at a particular PNGS might
be accomplished in that contacts between PGT128 and the
Asn301gp120-linked high-mannose glycan involve only the core
pentasaccharide (37), a portion that is common to both high-
mannose and complex-type N-glycans. This raises the possibility
that PGT128 binding would not be abrogated by a complex-type
N-glycan attached to Asn301gp120; indeed the Asn301gp120-at-
tached carbohydrate appears to be a complex-type N-glycan in
gp120s that were analyzed by mass spectrometry (50, 60, 66) but
not in the gp120 outer domain construct used for the structural
studies, which was produced in GnTI −/− cells (37). By analogy,
although PGT121-like antibodies may prefer interactions with
a complex-type N-glycan, as suggested by our glycan microarray
results (Fig. 1E and SI Appendix, Fig. S6) and the liganded
PGT121 structure (Fig. 4), these antibodies may be able to ac-
commodate either a complex-type or a high-mannose glycan at
a PNGS through interactions with the core pentasaccharide,
possibly combined with contacts to the asparagine or nearby
protein residues.
Promiscuity in glycan recognition suggests a mechanism to ex-
plain why PGT121-like and 10-1074–like antibodies, like PGT128
(37), exhibit saturable curves in neutralization assays (SI Appendix,
Fig. S10C), in contrast to PG9 and PG16 neutralization curves,
which plateau at values less than 100% (33): Assuming that
PGT121, PGT128, and 10-1074 aremore promiscuouswith respect
toN-glycan recognition than PG9/PG16, then although the former
antibodies might prefer either complex-type (PGT121) or high-
mannose (PGT128) glycans, they could still bind to those spikes
and/or virions within a given strain that carry the less desirable
glycan at a particular N-linked site (perhaps by interacting with
only the pentasaccharide core). In contrast, PG9/PG16 may have
an absolute requirement for high-mannose N-glycans and there-
fore would be unable to neutralize all virions in a heterogeneous
mixture of viruses with different glycan compositions, thereby ra-
tionalizing the shallow neutralization curves that plateau at less
than 100% neutralization (33).
Promiscuity with respect to carbohydrate interactions would be
an advantageous adaptation for an HIV antibody as a mechanism
ensuring neutralization of all viruses within a given strain. This
suggests that immunogens should be designed and produced such
that they can contain complex-type N-glycans to elicit antibodies
that can recognize these structures. Previous studies of carbohy-
drate-dependent HIV antibodies characterized interactions with
high-mannose N-glycans; our functional and structural studies of
PGT121-like antibodies now provide information regarding HIV
antibodies that likely recognize complex-type, as well as high-
mannose, N-glycans in their epitopes on gp120. PGT121 is a mem-
ber of a large group of neutralizing antibodies that recognize theV3
region of HIV (30, 39, 69–71), which has variable amino acid se-
quence and carbohydrate composition in different HIV isolates
(71). Nevertheless, there is sufﬁcient conservation that antibodies
against the V3 region can be broadly neutralizing by targeting the
V3 crown (71) or carbohydrates and the base of the V3 loop
(PGT121 and PGT128). The diversity of glycan and peptide rec-
ognition by the combination of PGT121, 10-1074, and PGT128
appears to disarm theHIV glycan shield. Thus, vaccines designed to
elicit antibodies to this region would likely be most effective by in-
cluding epitopes recognized by all types of V3 antibodies.
Materials and Methods
Single B-Cell RT-PCRs and IgGeneAnalyses. Single-cell sorting of gp140+CD19+IgG+
B cells from patient 10 (pt10) (referred to as patient 17 in ref. 32) PBMCs, cDNA
synthesis, and nested PCR ampliﬁcations of Ig genes were performed in a pre-
vious study (39). Igλ genes expressed by PGT121 clonal variants were PCR am-
pliﬁed using a forward primer (L-Vλ3–21*02: 5′ CTGGACCGTTCTCCTCCTCG 3′)
farther upstream in the leader region to avoid the potentially mutated region
(31). All PCR products were sequenced and analyzed for Ig gene use, CDR3
analyses, and number of VH/Vκ somatic hypermutations (IgBLAST, www.ncbi.
nlm.nih.gov/igblast; and IMGT, www.imgt.org). Multiple sequence alignments
were performed using the MacVector program (v.12.5.0) with the ClustalW
analysis function (default parameters) and were used to generate dendrograms
by the neighbor-joining method (with Best tree mode and outgroup rooting).
Alternatively, dendrograms shown in Figs. 1E, 2A, and 4D were generated using
the UPGMA method (with Best tree mode).
Cloning and Production of Antibodies. Puriﬁed digested PCR products were
cloned into human Igγ1-, or Igλ-expressing vectors as previously described
(40). Vectors containing IgH and Igλ genes were then sequenced and com-
pared with the original PCR product sequences. PGT121 and 10-303 shared
the same Igλ gene and had 1 aa difference in position 2 of the IgH gene (SI
Appendix, Fig. S2); therefore to produce the PGT121 IgG, we used the 10-303
Igλ gene and a PGT121 IgH gene generated by introducing a single sub-
stitution (V2M) into the 10-303 IgH gene by site-directed mutagenesis
(QuikChange Site-Directed Mutagenesis Kit; Stratagene). To generate His-
tagged Fabs, the PGT121 and 10-1074 VH genes were subcloned into a 6xHis-
IgCγ1 expression vector generated by modifying our standard Igγ1 vector
(41) to encode the IgG1 CH1 domain followed by a 6x-His tag. IgH DNA
fragments encoding PGT121GM (S32Y, K53D, S54R, N58T, H97R, and T100lY)
and 10-1074GM (Y32S, D53K, R54S, T58N, R97H, and Y100lT) mutant anti-
bodies were obtained as a synthetic minigene (IDT) and subcloned into Igγ1-
expressing vectors. Antibodies and Fab fragments were produced by tran-
sient transfection of IgH and IgL expression plasmids into exponentially
growing HEK 293T cells (ATCC; CRL-11268), using the polyethyleneimine
(PEI)-precipitation method (39). IgG antibodies were afﬁnity puriﬁed using
Protein G Sepharose beads (GE Healthcare) according to the manufacturer’s
instructions. Fab fragments were afﬁnity puriﬁed using HisPur Cobalt Resin
(Thermo Scientiﬁc) as described below.
HIV-1 Env Proteins. Alanine mutations were introduced into the pYU-2 gp120
vector (gift of J. Sodroski, Harvard Medical School) at positions 301–303 (Asn-
Asn-Thr), 324–325 (Gly-Asp), and 332 (Asn) (HXBc2 amino acid numbering),
using the QuikChange Site-Directed Mutagenesis kit (Stratagene) according
to the manufacturer’s instructions. The same procedure was used to gen-
erate “double-glycan” mutants by introducing single alanine mutations in
the pYU-2 gp120N332A vector at each PNGS located between Asn262gp120
and Asn406gp120. Site-directed mutations were veriﬁed by DNA sequencing.
Expression vectors encoding YU-2 gp140 (72), YU-2 gp120, HXB2c gp120core
(73), and HXB2c 2CCcore (74) proteins and YU-2 gp120 mutant proteins were
used to transfect HEK 293T cells as previously described (39). To produce















high-mannose-only YU-2 gp120 protein (gp120kif), 25 μM kifunensine (Enzo
Life Sciences) was added at the time of transfection. Culture supernatants
were harvested and concentrated using centrifugation-based ﬁltration
devices (Vivacell 100; Sartorius Stedim Biotech) that allowed buffer ex-
change of the samples into 10 mM imidazole, 50 mM sodium phosphate, 300
mM sodium chloride, pH 7.4. Proteins were puriﬁed by afﬁnity chromatog-
raphy, using HisPur Cobalt Resin (Thermo Scientiﬁc) according to the man-
ufacturer’s instructions. For deglycosylation reactions, 50 μg of HEK 293T
cell-produced YU-2 gp120 in PBS was digested overnight at 37 °C with 200
units of PNGase F (New England Biolabs) or 10,000 units of Endo Hf (New
England Biolabs) in their respective reaction buffers without denaturing
agents. After buffer exchange into PBS using Centrifugal Filters (Amicon
Ultra, Millipore), glycosidase-treated gp120s (200 ng) were examined by SDS/
PAGE, using a 4–12% NuPAGE gel (Invitrogen) followed by silver staining
(Pierce Silver Stain Kit; Thermo Scientiﬁc).
ELISAs. High-binding 96-well ELISA plates (Costar) were coated overnight
with 100 ng/well of puriﬁed gp120 in PBS. After washing, the plates were
blocked for 2 h with 2% (wt/vol) BSA, 1 μM EDTA, and 0.05% Tween-PBS
(blocking buffer) and then incubated for 2 h with IgGs at concentrations of
26.7 nM (or 427.2 nM for ELISAs using the YU-2 gp120 double-glycan
mutants) and seven consecutive 1:4 dilutions in PBS. After washing, the
plates were developed by incubation with goat HRP-conjugated anti-human
IgG antibodies (Jackson ImmunoReseach) (at 0.8 μg/mL in blocking buffer)
for 1 h and by addition of HRP chromogenic substrate (ABTS solution; Invi-
trogen) as previously described (39). Antibody binding to the selected
gp120V3 overlapping peptides was tested using a previously described pep-
tide-ELISA method (39). For competition ELISAs, gp120-coated plates were
blocked for 2 h with blocking buffer and then incubated for 2 h with bio-
tinylated antibodies (at a concentration of 26.6 nM for PGT121, 0.21 nM for
10-1074, 0.43 nM for 10-996, and 1.67 nM for 10-1369) in 1:2 serially diluted
solutions of antibody competitors in PBS (IgG concentration range from 5.2 to
667 nM). Plates were developed as described above, using HRP-conjugated
streptavidin (Jackson ImmunoReseach) (at 0.8 μg/mL in blocking buffer). All
experiments were performed at least in duplicate.
Glycan Microarray Analysis. Microarrays were generated by robotically
printing glycan probes linked to lipid (neoglycolipids) onto nitrocellulose-
coated glass slides as described in refs. 75 and 76 at two levels (2 and 5 fmol/
spot) in duplicate. Binding assays were performed with microarrays con-
taining 15 neoglycolipids derived from N-glycans of high-mannose and
complex types. The sequences of the probes are shown in SI Appendix, Fig.
S6A. In brief, antibodies were tested at 50 μg/mL, and binding was detected
with biotinylated anti-human IgG (Vector) followed by AlexaFluor 647-la-
beled streptavidin (Molecular Probes).
Surface Plasmon Resonance. Experiments were performed using a Biacore
T100 as described previously (77). Brieﬂy, YU-2 gp140 and gp120 proteins
were primary-amine coupled on CM5 chips (Biacore) at a coupling density of
300 response units (RU). Anti-gp120 IgGs and the GL precursor were injected
over ﬂow cells at 1 μM and 10 μM, respectively, at ﬂow rates of 35 μL/min
with 3-min association and 5-min dissociation phases. The sensor surface was
regenerated by a 30-s injection of 10 mM glycine·HCl, pH 2.5, at a ﬂow rate
of 50 μL/min. Dissociation [kd (s−1)], association [ka (M−1·s−1)], and binding
constants [KD (M) or KA (M
−1)] were calculated from kinetic analyses after
subtraction of backgrounds using a 1:1 binding model without a bulk re-
ﬂective index (RI) correction (Biacore T100 Evaluation software). Binding
constants for bivalent IgGs calculated using a 1:1 binding model are referred
to in the text as “apparent” afﬁnities to emphasize that the KD values in-
clude potential avidity effects.
Neutralization Assays. Virus neutralization was evaluated using a luciferase-
based assay in TZM.bl cells as previously described (49). The HIV-1 pseudo-
viruses tested contained mostly tier-2 and tier-3 viruses (78) (SI Appendix,
Tables S2 and S3). High-mannose-only pseudoviruses were produced in wild-
type cells treated with 25 μM kifunensine (Enzo Life Sciences) (SI Appendix,
Fig. S7C) or in HEK 293S GnTI−/− cells (SI Appendix, Fig. S7D). Nonlinear re-
gression analysis was used to calculate concentrations at which half-maximal
inhibition was observed (IC50 values). Neutralization activities were also
evaluated with a previously characterized PBMC-based assay, using infection
with primary HIV-1 variants (n = 95) isolated from clade B-infected donors
with known seroconversion dates either between 1985 and 1989 (“historical
seroconverters,” n = 14) or between 2003 and 2006 (“contemporary sero-
converters,” n = 21) (51, 52). Neutralization activity for each antibody was
calculated using GraphPad Prism software (v5.0b) as area under the best-ﬁt
curve, which ﬁts the proportion of viruses neutralized over IC50 values
ranging from 0.001 to 50 μg/mL. Relative area under the curve (RAUC) values
were derived by normalizing all AUC values by the highest value (obtained
with 10-1074).
Statistical Analyses. Statistical analyses were performed with the GraphPad
Prism software (v5.0b). Neutralization potencies in the TZM-bl assay against
the selected panel of nine virus strains vs. the apparent binding afﬁnities of
the antibodies for gp120 and gp140 were analyzed using Spearman’s cor-
relation test. The Mann–Whitney test was used to compare (i) afﬁnities for
gp120/gp140 of antibodies belonging to the PGT121 or 10-1074 group and
(ii) neutralization activities against viruses isolated from historical and
contemporary seroconverters.
Crystallization and Structure Determinations. Crystallization, data collection,
structure determinations, and analyses are described in detail in SI Appendix. The
atomic models were reﬁned to 3.0-Å resolution for PGT121 Fab (Rwork = 21.6%;
Rfree = 26.4%), 1.9-Å resolution for 10-1074 Fab (Rwork = 18.7%; Rfree = 22.3%),
2.4-Å resolution for four GL Fab molecules (Rwork = 19.4%; Rfree = 23.7%), and
2.4-Å resolution for liganded PGT121 Fab (Rwork = 20.1%; Rfree = 24.9%). The
atomic model of PGT121 Fab contains 95.2%, 4.9%, and 0.0% of the residues in
the favored, allowed, and disallowed regions of the Ramachandran plot, re-
spectively (10-1074 Fab, 98.8%, 0.9%, and 0.2%; GL Fab, 96.0%, 3.8%, and
0.23%; and liganded PGT121 Fab, 96.7%, 3.1%, and 0.2%).
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